Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
ESMO Open|September 15, 2022
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumorsC Le Tourneau, H Becker, R Claus, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2005
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Robert H Bradbury, Laurent F A Hennequin, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2006
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokineticsPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 ReceptorsBernard Barlaam, Judith Anderton, Peter Ballard, et al.
Bioorganic & Medicinal Chemistry Letters|March 7, 2006
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitorsLaurent F A Hennequin, Peter Ballard, F Tom Boyle, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocketPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Bioorganic & Medicinal Chemistry Letters|September 18, 2007
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Bernard C Barlaam, Robert H Bradbury, et al.
Breast (Edinburgh, Scotland)|November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseP Gougis, M Carton, C Tchokothe, et al.
ESMO Open|May 13, 2025
Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II studyE Samalin, L Evesque, A Turpin, et al.
Pageof 1